Home > Neurology > Dexamethasone may curb efficacy of immune-checkpoint blockade in glioblastoma

Dexamethasone may curb efficacy of immune-checkpoint blockade in glioblastoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Clinical Cancer Research
Reuters Health - 03/12/2020 - Dexamethasone given to combat cerebral edema in patients with glioblastoma may negatively affect immunotherapy, according to work in mice and clinical data. "There are many biologic, endogenous factors contributing to immunosuppression and immune evasion in glioblastoma," said Dr. David A. Reardon of Harvard Medical School, in Boston. "Our work highlights a critical exogenous and iatrogenic factor - the use of dexamethasone for the treatment of symptomatic cerebral edema - that represents an additional and significant potential hurdle for immunotherapy among patients afflicted with these devastating tumors," he told Reuters Health by email. In a statement, Dr. Reardon noted that cerebral edema is a common, potentially life-threatening complication in glioblastoma patients. Corticosteroid treatment can help suppress the inflammation in the brain, he added. Dr. Reardon and colleagues first studied the effects of dexamethason...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on